For KRAS-mutant lung cancers in particular, identifying vulnerabilities associated with recurring co-occurring mutations in tumor suppressor genes could enable the development of biomarker-driven combination therapies with enhanced activity in distinct subsets of patients. This evidence concerns the gene KRAS and lung carcinoma.